The DOI matches its Crossref record; 20 of the 20 references it cites were found in a registry or an index.
Long-Term Adherence to Evidence-Based Secondary Prevention Therapies in Coronary Artery Disease
Open accessAbstract
Background— Studies have examined the use of evidence-based therapies for coronary artery disease (CAD) in the short term and at hospital discharge, but few have evaluated long-term use. Methods and Results— Using the Duke Databank for Cardiovascular Disease for the years 1995 to 2002, we determined the annual prevalence and consistency of self-reported use of aspirin, β-blockers, lipid-lowering agents, and their combinations in all CAD patients and of angiotensin-converting enzyme inhibitors (ACEIs) in those with and without heart failure. Logistic-regression models identified characteristics associated with consistent use (reported on ≥2 consecutive follow-up surveys and then through death, withdrawal, or study end), and Cox proportional-hazards models explored the association of consistent use with mortality. Use of all agents and combinations thereof increased yearly. In 2002, 83% reported aspirin use; 61%, β-blocker use; 63%, lipid-lowering therapy use; 54%, aspirin and β-blocker use; and 39%, use of all 3. Consistent use was as follows: For aspirin, 71%; β-blockers, 46%; lipid-lowering therapy, 44%; aspirin and β-blockers, 36%; and all 3, 21%. Among patients without heart failure, 39% reported ACEI use in 2002; consistent use was 20%. Among heart failure patients, ACEI use was 51% in 2002 and consistent use, 39%. Except for ACEIs among patients without heart failure, consistent use was associated with lower adjusted mortality: Aspirin hazard ratio (HR), 0.58 and 95% confidence interval (CI), 0.54 to 0.62; β-blockers, HR, 0.63 and 95% CI, 0.59 to 0.67; lipid-lowering therapy, HR, 0.52 and 95% CI, 0.42 to 0.65; all 3, HR, 0.67 and 95% CI, 0.59 to 0.77; aspirin and β-blockers, HR, 0.61 and 95% CI, 0.57 to 0.65; and ACEIs among heart failure patients, HR, 0.75 and 95% CI, 0.67 to 0.84. Conclusions— Use of evidence-based therapies for CAD has improved but remains suboptimal. Although improved discharge prescription of these agents is needed, considerable attention must also be focused on understanding and improving long-term adherence.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The Coronary Drug Project Research Group (1980) · New England Journal of Medicine · doi:10.1056/nejm198010303031804 · Cited by 659
Rogers, W. J., Canto, J. G., Lambrew, C. T., Tiefenbrunn, A. J., Kinkaid, B., Shoultz, D. A., Frederick, P. D., & Every, N. (2000) · Journal of the American College of Cardiology · doi:10.1016/s0735-1097(00)00996-7 · Cited by 657
Garber, M. C., Nau, D. P., Erickson, S. R., Aikens, J. E., & Lawrence, J. B. (2004) · Medical Care · doi:10.1097/01.mlr.0000129496.05898.02 · Cited by 519
Fonarow, G. C., Gawlinski, A., Moughrabi, S., & Tillisch, J. H. (2001) · The American Journal of Cardiology · doi:10.1016/s0002-9149(00)01519-8 · Cited by 511
Krumholz, H. M., Radford, M. J., Wang, Y., Chen, J., Heiat, A., & Marciniak, T. A. (1998) · JAMA · doi:10.1001/jama.280.7.623 · Cited by 494
Adverse outcomes of underuse of beta-blockers in elderly survivors of acute myocardial infarction
Soumerai, S. B. (1997) · JAMA · doi:10.1001/jama.277.2.115 · Cited by 486
Mehta, R. H. (2002) · JAMA · doi:10.1001/jama.287.10.1269 · Cited by 477
Ellis, J. J., Erickson, S. R., Stevenson, J. G., Bernstein, S. J., Stiles, R. A., & Fendrick, A. M. (2004) · Journal of General Internal Medicine · doi:10.1111/j.1525-1497.2004.30516.x · Cited by 323
Mukherjee, D., Fang, J., Chetcuti, S., Moscucci, M., Kline-Rogers, E., & Eagle, K. A. (2004) · Circulation · doi:10.1161/01.cir.0000112577.69066.cb · Cited by 314
Get With the Guidelines for Cardiovascular Secondary Prevention: Pilot Results
LaBresh, K. A., Ellrodt, A. G., Gliklich, R., Liljestrand, J., & Peto, R. (2004) · Archives of Internal Medicine · doi:10.1001/archinte.164.2.203 · Cited by 269
Fonarow, G. C., French, W. J., Parsons, L. S., Sun, H., & Malmgren, J. A. (2001) · Circulation · doi:10.1161/01.cir.103.1.38 · Cited by 226
Outpatient adherence to beta-blocker therapy after acute myocardial infarction
Butler, J., Arbogast, P. G., BeLue, R., Daugherty, J., Jain, M. K., Ray, W. A., & Griffin, M. R. (2002) · Journal of the American College of Cardiology · doi:10.1016/s0735-1097(02)02379-3 · Cited by 162
Muhlestein, J. B., Horne, B. D., Bair, T. L., Li, Q., Madsen, T. E., Pearson, R. R., & Anderson, J. L. (2001) · The American Journal of Cardiology · doi:10.1016/s0002-9149(00)01354-0 · Cited by 159
Ries, A. L. M., & Williams, M. A. P. (2001) · Journal of Cardiopulmonary Rehabilitation · doi:10.1097/00008483-200105000-00019 · Cited by 150
Health and Economic Benefits of Increased β-Blocker Use Following Myocardial Infarction
Phillips, K. A. (2000) · JAMA · doi:10.1001/jama.284.21.2748 · Cited by 112
Drug prescriptions after acute myocardial infarction: Dosage, compliance, and persistence
Simpson, E., Beck, C. A., Richard, H., Eisenberg, M. J., & Pilote, L. (2003) · American Heart Journal · doi:10.1067/mhj.2003.143 · Cited by 108
Krumholz, H. M., Vaccarino, V., Ellerbeck, E. F., Kiefe, C. I., Hennen, J. A., Kresowik, T. F., Gold, J. A., Jencks, S. F., & Radford, M. J. (1997) · The American Journal of Cardiology · doi:10.1016/s0002-9149(96)00819-3 · Cited by 72
Potential impact of evidence-based medicine in acute coronary syndromes: insights from GUSTO-IIb
Alexander, K. P., Peterson, E. D., Granger, C. B., Casas, A. C., de Werf, F. V., Armstrong, P. W., Guerci, A. D., Topol, E. J., & Califf, R. M. (1998) · Journal of the American College of Cardiology · doi:10.1016/s0735-1097(98)00466-5 · Cited by 68
Self-citationUnderuse of aspirin in a referral population with documented coronary artery disease
Califf, R. M., DeLong, E. R., Østbye, T., et al. (2002) · The American Journal of Cardiology · doi:10.1016/s0002-9149(01)02335-9 · Cited by 59
Self-citationCaskie, G. I. L., & Willis, S. L. (2004) · The Gerontologist · doi:10.1093/geront/44.2.176 · Cited by 53
Cited by
Medication Adherence: WHO Cares?
Brown, M. T., & Bussell, J. K. (2011) · Mayo Clinic Proceedings · doi:10.4065/mcp.2010.0575 · Cited by 1,928
Free, C., Phillips, G., Galli, L., Watson, L., Felix, L., Edwards, P., Patel, V., & Haines, A. (2013) · PLoS Medicine · doi:10.1371/journal.pmed.1001362 · Cited by 1,766
“Health care consumers decide whether to adhere to prescribed medication and determine when they seek health care [11].”
Medication Adherence: Its Importance in Cardiovascular Outcomes
Ho, P. M., Bryson, C. L., & Rumsfeld, J. S. (2009) · Circulation · doi:10.1161/circulationaha.108.768986 · Cited by 1,488
Rasmussen, J. N., Chong, A., & Alter, D. A. (2007) · JAMA · doi:10.1001/jama.297.2.177 · Cited by 975
Adherence to Drugs That Prevent Cardiovascular Disease: Meta-analysis on 376,162 Patients
Naderi, S. H., Bestwick, J. P., & Wald, D. S. (2012) · The American Journal of Medicine · doi:10.1016/j.amjmed.2011.12.013 · Cited by 846
Metadata
- Authors
- Newby, L. K., Allen LaPointe, N. M., Chen, A. Y., Kramer, J. M., Hammill, B. G., DeLong, E. R., Muhlbaier, L. H., & Califf, R. M.
- Venue
- Circulation
- Published
- 2006-01-17
- Volume
- 113
- Issue
- 2
- Pages
- 203-212
- ISSN
- 0009-7322 (ISSN-L)
- 1524-4539
- OpenAlex
- W2130321587
- Cited by
- 505
- References
- 20
- FWCI
- 25.52
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.